Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL

NCT07723911 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07723911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07723911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 9, 2026
Completion date
October 10, 2028
Enrollment
212 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

precursor b-cell acute lymphoblastic leukemia